Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Jonathan D. Campbell"'
Autor:
Ivett Jakab, Melanie D. Whittington, Elizabeth Franklin, Susan Raiola, Jonathan D. Campbell, Zoltán Kaló, R. Brett McQueen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Defining the value of healthcare is an elusive target, and depends heavily on the decision context and stakeholders involved. Cost-utility analysis and the quality-adjusted life year (QALY) have become the method and value definition of c
Externí odkaz:
https://doaj.org/article/893917d308bb45338a80136b69e6eedb
Autor:
Howard L. Kaufman, Michael B. Atkins, Prasun Subedi, James Wu, James Chambers, T. Joseph Mattingly, Jonathan D. Campbell, Jeff Allen, Andrea E. Ferris, Richard L. Schilsky, Daniel Danielson, J. Leonard Lichtenfeld, Linda House, Wendy K. D. Selig
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts t
Externí odkaz:
https://doaj.org/article/32134812e74f40ba9ecc09ba55ae0b31
Autor:
Nicolas Roche, Jonathan D. Campbell, Jerry A. Krishnan, Guy Brusselle, Alison Chisholm, Leif Bjermer, Mike Thomas, Eric van Ganse, Maarten van den Berge, George Christoff, Jennifer Quint, Nikolaos G. Papadopoulos, David Price
Publikováno v:
Clinical and Translational Allergy, Vol 9, Iss 1, Pp 1-17 (2019)
Abstract Introduction A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to
Externí odkaz:
https://doaj.org/article/082ce1f221b94bd5be5236169980bcc9
Autor:
Jonathan D. Campbell, Robert Perry, Nikolaos G. Papadopoulos, Jerry Krishnan, Guy Brusselle, Alison Chisholm, Leif Bjermer, Michael Thomas, Eric van Ganse, Maarten van den Berge, Jennifer Quint, David Price, Nicolas Roche
Publikováno v:
Clinical and Translational Allergy, Vol 9, Iss 1, Pp 1-11 (2019)
Abstract Background Evidence from observational comparative effectiveness research (CER) is ranked below that from randomized controlled trials in traditional evidence hierarchies. However, asthma observational CER studies represent an important comp
Externí odkaz:
https://doaj.org/article/5f29d9358af842118e7cc9aeb3de509c
Autor:
Michelle H. Leppert, Sharon N. Poisson, Stefan H. Sillau, Jonathan D. Campbell, P. Michael Ho, James F. Burke
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 6 (2019)
Background Incidence of cardiovascular disease in young adults is unabated. Increased prevalence of self‐reported atherosclerotic risk factors may be driving this trend. The goal of this study was to examine whether the prevalence of atheroscleroti
Externí odkaz:
https://doaj.org/article/30a1b0aa7307496c820566efbfcc4ab4
Autor:
William V. Padula, Miguel Cordero-Coma, Taygan Yilmaz, Michéal J. Gallagher, Jonathan D. Campbell
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 2, Iss 2 (2015)
**Background:** Approximately 3.75% of cases of blindness in the United States are caused by uveitis. Incurred clinical costs and lost productivity related to vision loss in these cases totals $3.58 billion annually. **Objective:** To evaluate wheth
Externí odkaz:
https://doaj.org/article/4e2a2e8cf0f14a0ca93ffd35b998a7f0
Autor:
David Yamamoto, Jonathan D. Campbell
Publikováno v:
Autoimmune Diseases, Vol 2012 (2012)
Objective. To provide a current and comprehensive understanding of the cost-effectiveness of DMTs for the treatment of MS by quantitatively evaluating the quality of recent cost-effectiveness studies and exploring how the field has progressed from pa
Externí odkaz:
https://doaj.org/article/d15a2df231ea48a88c815f0bfa7b9974
Publikováno v:
Value in Health. 25:744-750
This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing
Autor:
Boglarka Szegvari, András Inotai, Neil Hawkins, Lars Erik Kristensen, Mata Charokopou, Zoltán Kaló, Diana I. Brixner, Irina Mountian, Jonathan D. Campbell, Ivett Jakab
Publikováno v:
Inotai, A, Jakab, I, Brixner, D, Campbell, J D, Hawkins, N, Kristensen, L E, Charokopou, M, Mountian, I, Szegvari, B & Kaló, Z 2021, ' Proposal for capturing patient experience through extended value frameworks of health technologies ', Journal of Managed Care and Specialty Pharmacy, vol. 27, no. 7, pp. 936-947 . https://doi.org/10.18553/JMCP.2021.27.7.936
BACKGROUND: Inclusion of patient experience (PEx) in health technology assessment (HTA) has become increasingly important; however, no harmonized approach exists to help manufacturers or decision makers ensure PEx considerations are fair, consistent,
Publikováno v:
PharmacoEconomics Open
Background Traditionally, the economic value of health technologies is assessed with cost-effectiveness (CE) and budget impact (BI) analyses. However, the evaluation of rare disease therapies often considers novel value criteria. Multi-criteria decis